Wurst Keele E, Shukla Amit, Muellerova Hana, Davis Kourtney J
1Worldwide Epidemiology, GlaxoSmithKline R&D, Research Triangle Park , NC , USA.
COPD. 2014 Sep;11(5):521-30. doi: 10.3109/15412555.2014.922064. Epub 2014 Jun 19.
This retrospective cohort study aimed to analyze the prescribing practices of general practitioners treating patients with newly diagnosed chronic obstructive pulmonary disease (COPD), and to assess characteristics associated with initial pharmacotherapy. Patients were identified in the General Practice Research Database, a population-based UK electronic medical record (EMR) with data from January 1, 2008 to December 31, 2009. Patient characteristics, prescribed COPD pharmacotherapies (≤12 months before diagnosis and within 3 months following diagnosis), co-morbidities, hospitalizations, and events indicative of a possible COPD exacerbation (≤12 months before diagnosis) were analyzed in 7881 patients with newly diagnosed COPD. Most patients (64.4%) were prescribed COPD pharmacotherapy in the 12 months before diagnosis. Following diagnosis, COPD pharmacotherapy was prescribed within 3 months in 85.0% of patients. Short-acting bronchodilators alone (22.9%) or inhaled corticosteroids + long-acting beta-2 agonists (ICS+LABA, 22.1%) were prescribed most frequently. Compared with other pharmacotherapies, the prevalence of severe airflow limitation was highest in patients prescribed ICS+LABA+long-acting muscarinic antagonists (LAMA). Moderate-to-severe dyspnea was identified most frequently in patients prescribed a LAMA-containing regimen. Patients prescribed an ICS-containing regimen had a higher prevalence of asthma or possible exacerbations recorded in the EMR than those not prescribed ICS. In conclusion, pharmacotherapy prescribed at initial COPD diagnosis varied by disease severity indicators as assessed by airflow limitation, dyspnea, history of asthma, and possible exacerbations. Frequent prescription of COPD pharmacotherapies before the first-recorded COPD diagnosis indicates a delay between obstructive lung disease presentation in primary care practice and assignment of a medical diagnosis.
这项回顾性队列研究旨在分析全科医生对新诊断为慢性阻塞性肺疾病(COPD)患者的处方习惯,并评估与初始药物治疗相关的特征。在英国基于人群的电子病历(EMR)——全科医疗研究数据库中识别患者,该数据库包含2008年1月1日至2009年12月31日的数据。对7881例新诊断为COPD的患者分析了其患者特征、处方的COPD药物治疗(诊断前≤12个月和诊断后3个月内)、合并症、住院情况以及提示可能的COPD加重的事件(诊断前≤12个月)。大多数患者(64.4%)在诊断前12个月内接受了COPD药物治疗。诊断后,85.0%的患者在3个月内接受了COPD药物治疗。最常处方的是单独使用短效支气管扩张剂(22.9%)或吸入性糖皮质激素+长效β2激动剂(ICS+LABA,22.1%)。与其他药物治疗相比,在接受ICS+LABA+长效毒蕈碱拮抗剂(LAMA)治疗的患者中,严重气流受限的患病率最高。在接受含LAMA方案治疗的患者中,中重度呼吸困难最为常见。与未接受ICS治疗的患者相比,接受含ICS方案治疗的患者在EMR中记录的哮喘或可能加重的患病率更高。总之,根据气流受限、呼吸困难、哮喘病史和可能加重情况评估,COPD初始诊断时开具的药物治疗因疾病严重程度指标而异。在首次记录COPD诊断之前频繁开具COPD药物治疗表明基层医疗实践中阻塞性肺病出现与医学诊断之间存在延迟。